US Patent

US7722856 — Process for the production of a radioactive aerosol

Method of Use · Assigned to Cyclomedica Australia Pty Ltd · Expires 2031-02-24 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for producing a radioactive aerosol suitable for medical diagnosis, specifically using technetium TC-99M labeled carbon.

USPTO Abstract

A method for forming an inhalable isotope compound suitable for use in patient medical diagnosis, the method comprising the steps of: (a) electrolytic loading of a carbon crucible with the isotope; (b) sublimating any isotope carrier in the crucible; (c) ablating the isotope in a carbon crucible, forming an ablation aerosol; (d) directly delivering the aerosol for immediate use by a patient. The isotope can comprise technetium.

Drugs covered by this patent

technetium-tc-99m-labeled-carbon (TECHNETIUM TC-99M LABELED CARBON)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4442`	—	technetium-tc-99m-labeled-carbon

Patent Metadata

Patent number: US7722856
Jurisdiction: US
Classification: Method of Use
Expires: 2031-02-24
Drug substance claim: No
Drug product claim: No
Assignee: Cyclomedica Australia Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.